USS, Ignoring the typos at clinicaltrials.gov, our
Post# of 155046

The FDA cleared the company to commence the Phase II trial, as announced in the 11/04/2024 PR. First patient dosing was announced on 6/24/2025. How to feel about the sounds of silence from a cancer patient's perspective?
Quoting Dr. Lalezari from the 12/17/2024 Shareholder Letter: "I am pleased to confirm that the Company has sufficient cash and drug supplies on hand to complete its clinical priorities in 2025."

